Alastair Lawson - Biog

 

Alastair is responsible for UCB's Structure-Based Drug Design and Antibody Technology worldwide.  He has been with UCB Celltech since 1983, and was closely involved with the development of MylotargÒ.  More recently, he led UCB's SLAM (Selected Lymphocyte Antibody Method) antibody discovery platform and now heads UCB's A2HiTä technology, in which biologically-derived information is being used to power small molecule design.